Current Insights into 3D Bioprinting: An Advanced Approach for Eye Tissue Regeneration

Pharmaceutics, Journal Year: 2021, Volume and Issue: 13(3), P. 308 - 308

Published: Feb. 26, 2021

Three-dimensional (3D) printing is a game changer technology that holds great promise for wide variety of biomedical applications, including ophthalmology. Through this emerging technique, specific eye tissues can be custom-fabricated in flexible and automated way, incorporating different cell types biomaterials precise anatomical 3D geometries. However, despite the progress possibilities generated recent years, there are still challenges to overcome jeopardize its clinical application regular practice. The main goal review provide an in-depth understanding current status implementation bioprinting ophthalmology field order manufacture relevant such as cornea, retina conjunctiva. Special attention paid description most commonly employed methods, tissue engineering studies performed by at preclinical level. In addition, other issues related use ocular drug delivery, well both ethical regulatory aspects, analyzed. review, we aim raise awareness among research community report advances future directions apply advanced therapy regeneration field.

Language: Английский

---

Interleukin-20 is involved in dry eye disease and is a potential therapeutic target

Journal of Biomedical Science, Journal Year: 2022, Volume and Issue: 29(1)

Published: June 9, 2022

Abstract Background Dry eye disease (DED) is a common in ophthalmology, affecting millions of people worldwide. Recent studies have shown that inflammation the core mechanism DED. IL-20 proinflammatory cytokine involved various inflammatory diseases. Therefore, we aimed to explore role this pathogenesis DED and evaluate therapeutic potential anti-IL-20 monoclonal antibody (mAb) 7E for treatment. Methods Clinical tear samples from patients with non-DED controls were collected their protein levels determined. We established three animal models efficacy Benzalkonium chloride (BAC)-induced over-evaporative DED, extra-orbital lacrimal gland excision (LGE)-induced aqueous tear-deficient desiccating stress (DS)-induced combined investigate IL-20. The was neutralize activity. effects or on human corneal epithelial cells macrophages under hyperosmotic analyzed. topically applied eyes models. Results significantly upregulated tears corneas Under stress, expression induced via NFAT5 activation cells. suppressed stress-induced macrophages. cell death protected death. Blocking signaling mice BAC-induced, LGE-induced, DS-induced by reducing symptoms inhibiting responses, macrophage infiltration, apoptosis, Th17 populations conjunctiva draining lymph nodes. Conclusions Our results demonstrated functions presented option condition. Graphical

Language: Английский

---

Gut-derived butyrate suppresses ocular surface inflammation

Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)

Published: March 16, 2022

Abstract Dry eye is a common ocular inflammatory disorder characterized by tear film instability and reduced production. There increasing evidence that homeostasis of the surface impacted intestinal microbiome. We are interested in investigating potential role microbially produced small molecules mediating interaction between microbiota surface. One such molecule butyrate, short-chain fatty acid (SCFA) certain members gut through fermentation dietary fiber. Here we show SCFA transporter SLC5A8 expressed vivo murine conjunctival corneal epithelium. Pre-treatment vitro epithelial cultures or bone marrow-derived dendritic cells (BMDCs) with phenylbutyrate (PBA) reduces lipopolysaccharide-induced pro-inflammatory Tnf expression. Corneal BMDCs isolated from Slc5a8 knockout mice unable to respond PBA pre-treatment, suggesting required for protective effect PBA. The treatment undergoing desiccating stress (DS) oral tributyrin, prodrug form inflammation at , this partially requires SLC5A8. Finally, expression analysis on tissue subjected DS without tributyrin revealed downregulated genes involved Type I interferon signaling. Together these data support our hypothesis SCFAs participate maintenance homeostasis.

Language: Английский

---

An Overview of the Dry Eye Disease in Sjögren’s Syndrome Using Our Current Molecular Understanding

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(2), P. 1580 - 1580

Published: Jan. 13, 2023

Sjögren's syndrome is a chronic and insidious auto-immune disease characterized by lymphocyte infiltration of exocrine glands. The patients typically present with ocular surface diseases related to dry eye other systemic manifestations. However, due the high prevalence lack objective clinically reliable diagnostic tools, discriminating (SSDE) from non-Sjögren's (NSSDE) remains challenge for clinicians. Diagnosing SS important improve quality life through timely referral workups, as associated serious complications such lymphoma autoimmune diseases. purpose this article describe current molecular understanding its implications novel modalities on horizon. A literature review pre-clinical clinical studies published between 2016 2022 was conducted. SSDE pathophysiology immunology pathways have become better understood in recent years. Novel modalities, tear saliva proteomics well exosomal biomarkers, provide hope

Language: Английский

---

MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: July 11, 2023

Abstract Inflammation is a key factor in the pathogenesis of dry eye disease (DED). We aimed to investigate role microRNA-146a (miR-146a) regulating corneal inflammation mouse model benzalkonium chloride (BAC)-induced and TNF-α-induced NF-κB signaling pathway human epithelial cells (HCECs). A was established by administering with BAC BALB/c mice, expression TNF-α, IL-1β, IL-6, IL-8, cyclooxygenase 2 (COX2), interleukin-1 receptor-associated kinase 1 (IRAK1) TNF 6 (TRAF6) corneas mice significantly increased; this accompanied upregulation miR-146a activation pathway. In vitro, TNF-α induced HCECs, while inhibitor SC-514 reduced miR-146a. Overexpression decreased IRAK1 TRAF6, which have been identified as targets Furthermore, overexpression suppressed p65 translocation from cytoplasm nucleus. Moreover, attenuated COX2 intercellular adhesion molecule (ICAM1), inhibition exerted opposite effect. Our results suggest that mediates inflammatory response DED. MiR-146a negatively regulates HCECs through IRAK1/TRAF6/NF-κB pathway, may serve potential therapeutic approach for treatment

Language: Английский

---

The Potential Role of Regulated Cell Death in Dry Eye Diseases and Ocular Surface Dysfunction

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(1), P. 731 - 731

Published: Jan. 1, 2023

The research on new treatments for dry eye diseases (DED) has exponentially grown over the past decades. increased prevalence of conditions, particularly in younger population, received much attention. Therefore, it is utmost importance to identify novel therapeutical targets. Regulated cell death (RCD) an essential process control biological homeostasis tissues and organisms. identification different mechanisms RCD stimulated their involvement human pathologies. Whereas apoptosis been widely studied DED included vicious cycle, role still needs be completely elucidated. In this review, we will explore potential roles types ocular surface dysfunction. Starting from evidence oxidative stress inflammation pathology, analyse therapeutic applications following principal mechanisms: ferroptosis, necroptosis, pyroptosis.

Language: Английский

---

NLRP3 Inflammasome as a Potential Therapeutic Target in Dry Eye Disease

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 10866 - 10866

Published: June 29, 2023

Dry eye disease (DED) is a multifactorial ocular surface disorder arising from numerous interrelated underlying pathologies that trigger self-perpetuating cycle of instability, hyperosmolarity, and damage. Associated discomfort visual disturbance contribute negatively to quality life. Ocular inflammation has been increasingly recognised as playing key role in the pathophysiology chronic DED. Current readily available anti-inflammatory agents successfully relieve symptoms, but often without addressing pathophysiological mechanism. The NOD-like receptor protein-3 (NLRP3) inflammasome pathway recently implicated driver inflammation, reported pre-clinical clinical studies This review discusses intimate relationship between DED highlights involvement development DED, describes existing therapies their limitations, evaluates potential context therapeutic landscape target for effective treatment disease.

Language: Английский

---

Puerarin alleviates hyperosmotic stress-induced oxidative stress, inflammation, apoptosis and barrier damage of human corneal epithelial cells by targeting SIRT1/NLRP3 signaling

Toxicology in Vitro, Journal Year: 2023, Volume and Issue: 94, P. 105722 - 105722

Published: Oct. 21, 2023

Language: Английский

---

Poloxamer sols endowed with in-situ gelability and mucoadhesion by adding hypromellose and hyaluronan for prolonging corneal retention and drug delivery

Drug Delivery, Journal Year: 2023, Volume and Issue: 30(1)

Published: Jan. 1, 2023

The purpose of this study was to develop poloxamer (P407)-based in-situ thermogellable hydrogels with reducing concentration P407 by adding hypromellose (HPMC) and enhancing mucoadhesion resulting hyaluronic acid (HA) for prolonging ocular delivery hydroxypropyl-β-cyclodextrin (HPβCD)-solubilized testosterone (TES). Results demonstrated that 0.5% TES solution successfully solubilized 10% HPβCD. Non-gellable 13% sol became gellable 2.0-2.5% HPMC mucoadhesibility further imporved 0.3% HA-L (low MW) or HA-H (high MW). Optimized HPβCD-solubilized P407-based enhancement comprised P407, 2.5% HPMC, HA-H. Furthermore, rheological measurements under simulated eye blinking confirmed non-thixotropic properties optimized could be spreaded evenly retain a greater amount drug-loaded on the surface longer period prolong drug delivery. Compared conventional drops, prolonged residence time from ex vivo in studies were observed, indicating relationships between performances. It concluded thermosensitive formulated HA potentially accomplishing effective clinical treatment DED.

Language: Английский

---

Anti-inflammatory and antioxidative effects of gallic acid on experimental dry eye: in vitro and in vivo studies

Eye and Vision, Journal Year: 2023, Volume and Issue: 10(1)

Published: May 1, 2023

Abstract Background To investigate the anti-inflammatory and antioxidative effects of gallic acid (GA) on human corneal epithelial cells (HCECs) RAW264.7 macrophages as well its therapeutic in an experimental dry eye (EDE) mouse model. Methods A cell counting kit-8 (CCK-8) assay was used to test cytotoxicity GA. The effect GA migration evaluated using a scratch wound healing assay. vitro were tested hypertonic model inflammatory (RAW264.7 cells). vivo biocompatibility detected by irritation tests rabbits, whereas preventive EDE. Results In range 0–100 μM, showed no or HCECs did not delay monolayer within 24 h. Ocular tolerance good after seven days. terms activity, significantly reduced intracellular reactive oxygen species (ROS) lipopolysaccharide (LPS) activated exposed hyperosmotic stress. Furthermore, pre-treatment with GA, expression levels nuclear factor E2-related 2 (Nrf2), heme oxygenase-1 (HO-1), NADPH quinone oxidoreductase-1 (NQO-1) upregulated macrophages. also exhibits excellent properties. This is mainly demonstrated ability effectively downregulate transcription factor-κB (NF-κB) pathway LPS-activated reduce factors, such nitric oxide (NO), interleukin 6 (IL-6), tumor necrosis alpha (TNF-α). efficacy testing results EDE that can prevent inhibit apoptosis (CECs), factors cornea conjunctiva protect goblet cells. Conclusion indicate possesses potent properties apparent μM. It promising drop formulation for effective prevention treatment disease (DED).

Language: Английский

---